The earnings call was largely positive, driven by strong revenue growth and successful product performance from RUCONEST and Joenja. Despite some challenges in operating expenses and patient reclassification, the company has increased its revenue guidance and is making progress in its pipeline expansion, indicating a strong overall outlook.

Company Guidance -

Q3 2025

In the Q2 2025 earnings call, Pharming CEO Fabrice Chouraqui highlighted significant financial achievements and updated guidance. The company reported a 26% increase in total revenues compared to the same quarter last year, driven by RUCONEST's 28% year-on-year growth and accelerated patient uptake of Joenja. The operating profit reached $12.9 million, excluding $2 million in nonrecurring acquisition-related expenses. Pharming upgraded their full-year 2025 revenue guidance to $335-350 million, up from $325-340 million, reflecting a projected growth of 13-18%. The company also noted an increase in gross profit by 27% to $84.2 million, and a notable rise in cash and marketable securities from $108.9 million to $130.8 million by the end of the quarter, primarily due to positive net cash flows from operations. Pharming's focus remains on RUCONEST's continued double-digit growth and Joenja's expansion into new markets, with efforts to optimize operating expenses and further develop their promising late-stage pipeline.

Strong Revenue Growth

Total revenues grew by 26% in Q2 2025 compared to Q2 2024, with operating profit reaching $12.9 million from a previous loss.

Successful Product Performance

RUCONEST showed a 28% year-on-year growth, with Joenja also seeing significant patient uptake and revenue growth.

Increased Revenue Guidance

Pharming raised its 2025 total revenue guidance to between $335 million and $350 million.

Pipeline Expansion

Joenja's geographic expansion and potential pediatric label expansion are expected to facilitate further growth.

Positive Cash Flow

Cash and marketable securities increased from $108.9 million to $130.8 million due to net cash flows from operating activities.

Pharming Group (PHAR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHAR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	<0.01 / -	-0.02	―	―	―
Jul 31, 2025	2025 (Q2)	-0.10 / 0.06	-0.02	400.00% (+0.08)
May 08, 2025	2025 (Q1)	-0.03 / -0.22	-0.19	-15.79% (-0.03)
Mar 13, 2025	2024 (Q4)	0.02 / 0.05	-0.04	225.00% (+0.09)
Oct 24, 2024	2024 (Q3)	>-0.01 / -0.02	0.005	-500.00% (-0.03)
Aug 01, 2024	2024 (Q2)	>-0.01 / -0.02	0.01	-300.00% (-0.03)
May 08, 2024	2024 (Q1)	<0.01 / -0.19	-0.17	-11.76% (-0.02)
Mar 14, 2024	2023 (Q4)	<0.01 / -0.04	-0.205	80.49% (+0.16)
Oct 26, 2023	2023 (Q3)	-0.13 / <0.01	0.4	-98.75% (-0.40)
Aug 03, 2023	2023 (Q2)	-0.10 / 0.01	0.215	-95.35% (-0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHAR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$10.09	$11.11	+10.11%
May 08, 2025	$9.00	$10.01	+11.22%
Mar 13, 2025	$7.74	$8.74	+12.92%
Oct 24, 2024	$8.96	$8.30	-7.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pharming Group (PHAR) report earnings?

Pharming Group (PHAR) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Pharming Group (PHAR) earnings time?

Pharming Group (PHAR) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PHAR EPS forecast?

PHAR EPS forecast for the fiscal quarter 2025 (Q3) is <0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing